🔗 Visit the ClinicalTrials.gov page for NCT04193696
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | 54.30 |
| 2 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. | Lancet Oncol | 2008 | 23.93 |
| 3 | Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. | Nature | 2015 | 7.49 |
| 4 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. | Lancet | 2017 | 2.11 |
| 5 | Radiotherapy combination opportunities leveraging immunity for the next oncology practice. | CA Cancer J Clin | 2016 | 0.87 |